Metlife (NYSE:MET) Downgraded by ValuEngine

ValuEngine lowered shares of Metlife (NYSE:MET) from a hold rating to a sell rating in a research report released on Thursday, ValuEngine reports.

A number of other equities research analysts have also weighed in on the company. Morgan Stanley lifted their price objective on Metlife from $52.00 to $53.00 and gave the company an equal weight rating in a report on Wednesday, July 10th. Barclays lifted their price objective on Metlife from $52.00 to $55.00 and gave the company an overweight rating in a report on Wednesday, May 22nd. Citigroup set a $42.00 price objective on Metlife and gave the company a sell rating in a report on Thursday, May 23rd. UBS Group lifted their price objective on Metlife from $45.00 to $48.00 and gave the company a neutral rating in a report on Tuesday, April 9th. Finally, Deutsche Bank lifted their price objective on Metlife from $46.00 to $47.00 and gave the company a hold rating in a report on Friday, April 12th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $50.91.

MET traded down $1.04 during trading on Thursday, reaching $47.29. The company’s stock had a trading volume of 9,084,518 shares, compared to its average volume of 4,049,191. Metlife has a 52-week low of $37.76 and a 52-week high of $51.16. The firm has a fifty day moving average of $49.75. The company has a market capitalization of $45.93 billion, a P/E ratio of 8.77, a price-to-earnings-growth ratio of 1.05 and a beta of 1.09. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.14 and a quick ratio of 0.14.

Metlife (NYSE:MET) last announced its quarterly earnings data on Wednesday, July 31st. The financial services provider reported $1.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.07. Metlife had a return on equity of 9.75% and a net margin of 9.28%. The company had revenue of $16.45 billion for the quarter, compared to analyst estimates of $16.43 billion. During the same quarter in the previous year, the company earned $1.30 EPS. The firm’s revenue for the quarter was down 22.4% compared to the same quarter last year. As a group, research analysts anticipate that Metlife will post 5.63 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Tuesday, August 6th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a dividend yield of 3.72%. The ex-dividend date is Monday, August 5th. Metlife’s dividend payout ratio (DPR) is 32.65%.

Large investors have recently made changes to their positions in the company. Kavar Capital Partners LLC purchased a new stake in shares of Metlife during the 2nd quarter worth approximately $25,000. Osborn Williams & Donohoe LLC purchased a new stake in shares of Metlife during the 1st quarter worth approximately $26,000. Advisory Alpha LLC purchased a new stake in shares of Metlife during the 1st quarter worth approximately $27,000. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Metlife by 4,407.7% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 586 shares of the financial services provider’s stock worth $25,000 after acquiring an additional 573 shares in the last quarter. Finally, Meridian Wealth Management LLC purchased a new stake in shares of Metlife during the 1st quarter worth approximately $26,000. 75.75% of the stock is currently owned by institutional investors and hedge funds.

About Metlife

MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.

Featured Article: What does it mean to hold a stock in street name?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Metlife (NYSE:MET)

Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.